CHOPPI: A web tool for the analysis of immunogenicity risk from host cell proteins in CHO-based protein production

Biotechnology and Bioengineering

Volumn 111, Issue 11, 2014, Pages 2170-2182

  Bailey Kellogg, Chris ^a   Gutiérrez, Andres H ^b   Moise, Leonard ^b,c   Terry, Frances ^c   Martin, William D ^c   De Groot, Anne S ^b,c  

^a Dartmouth College   (United States)

^b UNIVERSITY OF RHODE ISLAND   (United States)

^c EpiVax Inc   (United States)

Author keywords

Biologic; CHO; Host cell protein; Immunogenicity; Immunoinformatics; T cell epitope

Indexed keywords

CELL ENGINEERING; CELLS; CYTOLOGY; EPITOPES; GENES; IMMUNE SYSTEM; MOLECULAR BIOLOGY; PASSIVE FILTERS; RISK ASSESSMENT; STANDARDS; T-CELLS;

BIOLOGIC; HOST CELL PROTEIN; IMMUNOGENICITY; IMMUNOINFORMATICS; T-CELL EPITOPES;

PROTEINS;

EPITOPE; HOST CELL PROTEIN; PROTEIN; PROTEOME; SIGNAL PEPTIDE; TRANSCRIPTOME; UNCLASSIFIED DRUG; BIOLOGICAL PRODUCT; RECOMBINANT PROTEIN;

AMINO ACID SEQUENCE; ANALYTIC METHOD; ANIMAL EXPERIMENT; ARTICLE; CHINESE HAMSTER OVARY PROTEIN PREDICTED IMMUNOGENICITY; CHO CELL LINE; CONTROLLED STUDY; CROSS REACTION; FEMALE; FOLLOW UP; GENE EXPRESSION; HUMAN; IMMUNE RESPONSE; IMMUNOGENICITY; MAJOR HISTOCOMPATIBILITY COMPLEX; MOUSE; NONHUMAN; OVARY CELL; PROTEIN EXPRESSION; REGULATORY T LYMPHOCYTE; RISK ASSESSMENT; RISK FACTOR; SOLID PHASE EXTRACTION; ANIMAL; BIOLOGY; CRICETULUS; DRUG CONTAMINATION; IMMUNOLOGY; INTERNET; METABOLISM; PROCEDURES;

ANIMALS; BIOLOGICAL PRODUCTS; CHO CELLS; COMPUTATIONAL BIOLOGY; CRICETULUS; DRUG CONTAMINATION; INTERNET; RECOMBINANT PROTEINS;

EID: 84925279274     PISSN: 00063592     EISSN: 10970290     Source Type: Journal    
DOI: 10.1002/bit.25286     Document Type: Article

References (48)

1. Baycin-Hizal D, Tabb DL, Chaerkady R, Chen L, Lewis NE, Nagarajan H, Sarkaria V, Kumar A, Wolozny D, Colao J, Jacobson E, Tian Y, O'Meally RN, Krag SS, Cole RN, Palsson BO, Zhang H, Betenbaugh M. 2012. Proteomic analysis of Chinese hamster ovary cells. J Proteome Res 11:5265-5276.
2. Becker J, Hackl M, Rupp O, Jakobi T, Schneider J, Szczepanowski R, Bekel T, Borth N, Goesmann A, Grillari J, Kaltschmidt C, Noll T, Pühler A, Tauch A, Brinkrolf K. 2011. Unraveling the Chinese hamster ovary cell line transcriptome by next-generation sequencing. J Biotechnol 156:227-235.
3. Brinkrolf K, Rupp O, Laux H, Kollin F, Ernst W, Linke B, Kofler R, Romand S, Hesse F, Budach WE, Galosy S, Müller D, Noll T, Wienberg J, Jostock T, Leonard M, Grillari J, Tauch A, Goesmann A, Helk B, Mott JE, Pühler A, Borth N. 2013. Chinese hamster genome sequenced from sorted chromosomes. Nat Biotechnol 31:694-695.
4. Camacho C, Coulouris G, Avagyan V, Ma N, Papadopoulos J, Bealer K, Madden TL. 2009. BLAST+: Architecture and applications. BMC Bioinformatics 10:421.
5. Casadevall N, Nataf J, Viron B, Kolta A, Kiladjian J-J, Martin-Dupont P, Michaud P, Papo T, Ugo V, Teyssandier I, Varet B, Mayeux P. 2002. Pure red-cell aplasia and antierythropoietin antibodies in patients treated with recombinant erythropoietin. N Engl J Med 346:469-475.
6. Champion K, Madden H, Dougherty J, Shacter E. 2005. Defining your product profile and maintaining control over it, Part 2. BioProcess Int 3:52-57.
7. Diamond B. 2003. Speculations on the immunogenicity of self proteins. Dev Biol 112:29-34.
8. Doneanu CE, Xenopoulos A, Fadgen K, Murphy J, Skilton SJ, Prentice H, Stapels M, Chen W. 2012. Analysis of host-cell proteins in biotherapeutic proteins by comprehensive online two-dimensional liquid chromatography/mass spectrometry. MAbs 4:24-44.
9. EMA. 2012. Draft guideline on similar biological medicinal products containing biotechnology-derived proteins as active substance: Quality issues. http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2012/05/WC500127960.pdf
10. FDA. 2012. Draft guidance for industry scientific considerations in demonstrating biosimilarity to a reference protein product. http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM291128.pdf
11. Gregory SH, Mott S, Phung J, Lee J, Moise L, McMurry JA, Martin W, De Groot AS. 2009. Epitope-based vaccination against pneumonic tularemia. Vaccine 27:5299-5306.
12. De Groot AS, Bishop EA, Khan B, Lally M, Marcon L, Franco J, Mayer KH, Carpenter CCJ, Martin W. 2004. Engineering immunogenic consensus T helper epitopes for a cross-clade HIV vaccine. Methods 34:476-487.
13. De Groot AS, Jesdale BM, Szu E, Schafer JR, Chicz RM, Deocampo G. 1997. An interactive Web site providing major histocompatibility ligand predictions: Application to HIV research. AIDS Res Hum Retroviruses 13:529-531.
14. De Groot AS, Martin W. 2009. Reducing risk, improving outcomes: Bioengineering less immunogenic protein therapeutics. Clin Immunol 131:189-201.
15. Grosenbaugh DA, Leard AT, Bergman PJ, Klein MK, Meleo K, Susaneck S, Hess PR, Jankowski MK, Jones PD, Leibman NF, Johnson MH, Kurzman ID, Wolchok JD. 2011. Safety and efficacy of a xenogeneic DNA vaccine encoding for human tyrosinase as adjunctive treatment for oral malignant melanoma in dogs following surgical excision of the primary tumor. Am J Vet Res 72:1631-1638.
16. Gutierrez AH, Moise L, De Groot AS. 2012. Of [hamsters] and men. Hum Vaccines Immunother 8:1172-1174.
17. Hai S-H, McMurry JA, Knopf PM, Martin W, De Groot AS. 2009. Immunogenicity screening using in silico methods: Correlation between T-cell epitope content and clinical immunogenicity of monoclonal antibodies. In: An Z, editor. Therapeutic Monoclonal Antibodies. Hoboken, NJ: John Wiley & Sons, Inc. p 417-437.
18. He L, De Groot AS, Gutierrez AH, Martin WD, Moise L, Bailey-Kellogg C. 2014. Integrated assessment of predicted MHC binding and cross-conservation with self reveals patterns of viral camouflage. BMC Bioinformatics 15:S1.
19. Higgins E. 2010. Carbohydrate analysis throughout the development of a protein therapeutic. Glycoconj J 27:211-225.
20. Inaba H, Moise L, Martin W, De Groot AS, Desrosiers J, Tassone R, Buchman G, Akamizu T, De Groot LJ. 2013. Epitope recognition in HLA-DR3 transgenic mice immunized to TSH-R protein or peptides. Endocrinology 154:2234-2243.
21. Inaba H, Pan D, Shin Y-H, Martin W, Buchman G, De Groot LJ. 2009. Immune response of mice transgenic for human histocompatibility leukocyte Antigen-DR to human thyrotropin receptor-extracellular domain. Thyroid Off J Am Thyroid Assoc 19:1271-1280.
22. Ipsen. 2012. Ipsen's partner Inspiration Biopharmaceuticals announces hold of phase III clinical trials evaluating IB1001 for the treatment and prevention of hemophilia B. http://www.ipsen.com/wp-content/uploads/2013/03/PR_IB1001-Clinical-Hold_EN_0.pdf
23. Jayapal KP, Wlaschin KF, Hu W-S, Yap MG. 2007. Recombinant protein therapeutics from CHO cells-20 years and counting. Chem Eng Prog 103:40-47.
24. Jin M, Szapiel N, Zhang J, Hickey J, Ghose S. 2010. Profiling of host cell proteins by two-dimensional difference gel electrophoresis (2D-DIGE): Implications for downstream process development. Biotechnol Bioeng 105:306-316.
25. Kim JY, Kim Y-G, Lee GM. 2012. CHO cells in biotechnology for production of recombinant proteins: Current state and further potential. Appl Microbiol Biotechnol 93:917-930.
26. Koren E, De Groot AS, Jawa V, Beck KD, Boone T, Rivera D, Li L, Mytych D, Koscec M, Weeraratne D, Swanson S, Martin W. 2007. Clinical validation of the "in silico" prediction of immunogenicity of a human recombinant therapeutic protein. Clin Immunol 124:26-32.
27. Koren E, Zuckerman LA, Mire-Sluis AR. 2002. Immune responses to therapeutic proteins in humans-Clinical significance, assessment and prediction. Curr Pharm Biotechnol 3:349-360.
28. Lewis NE, Liu X, Li Y, Nagarajan H, Yerganian G, O'Brien E, Bordbar A, Roth AM, Rosenbloom J, Bian C, Xie M, Chen W, Li N, Baycin-Hizal D, Latif H, Forster J, Betenbaugh MJ, Famili I, Xu X, Wang J, Palsson BO. 2013. Genomic landscapes of Chinese hamster ovary cell lines as revealed by the Cricetulus griseus draft genome. Nat Biotechnol 31:759-765.
29. McLachlan SM, Aliesky HA, Chen C-R, Chong G, Rapoport B. 2012. Breaking tolerance in transgenic mice expressing the human TSH receptor A-subunit: Thyroiditis, epitope spreading and adjuvant as a "double edged sword." PLoS ONE 7:e43517.
30. McMurry J, Sbai H, Gennaro ML, Carter EJ, Martin W, De Groot AS. 2005. Analyzing Mycobacterium tuberculosis proteomes for candidate vaccine epitopes. Tuberculosis (Edinb) 85:95-105.
31. Moise L, Buller RM, Schriewer J, Lee J, Frey SE, Weiner DB, Martin W, De Groot AS. 2011. VennVax, a DNA-prime, peptide-boost multi-T-cell epitope poxvirus vaccine, induces protective immunity against vaccinia infection by T cell response alone. Vaccine 29:501-511.
32. Moise L, Gutierrez AH, Bailey-Kellogg C, Terry F, Leng Q, Abdel Hady KM, Verberkmoes NC, Sztein MB, Losikoff PT, Martin WD, Rothman AL, De Groot AS. 2013. The two-faced T cell epitope: Examining the host-microbe interface with JanusMatrix. Hum Vaccines Immunother 9:1577-1586.
33. Moise L, Song C, Martin WD, Tassone R, De Groot AS, Scott DW. 2012. Effect of HLA DR epitope de-immunization of Factor VIII in vitro and in vivo. Clin Immunol 142:320-331.
34. Moss SF, Moise L, Lee DS, Kim W, Zhang S, Lee J, Rogers AB, Martin W, De Groot AS. 2011. HelicoVax: Epitope-based therapeutic Helicobacter pylori vaccination in a mouse model. Vaccine 29:2085-2091.
35. Omasa T, Onitsuka M, Kim W-D. 2010. Cell engineering and cultivation of Chinese hamster ovary (CHO) cells. Curr Pharm Biotechnol 11:233-240.
36. Osipovitch DC, Parker AS, Makokha CD, Desrosiers J, Kett WC, Moise L, Bailey-Kellogg C, Griswold KE. 2012. Design and analysis of immune-evading enzymes for ADEPT therapy. Protein Eng Des Sel PEDS 25:613-623.
37. Petersen TN, Brunak S, von Heijne G, Nielsen H. 2011. SignalP 4.0: Discriminating signal peptides from transmembrane regions. Nat Methods 8:785-786.
38. Pezzini J, Joucla G, Gantier R, Toueille M, Lomenech A-M, Le Sénéchal C, Garbay B, Santarelli X, Cabanne C. 2011. Antibody capture by mixed-mode chromatography: A comprehensive study from determination of optimal purification conditions to identification of contaminating host cell proteins. J Chromatogr A 1218:8197-8208.
39. Prasad S, Kohm AP, McMahon JS, Luo X, Miller SD. 2012. Pathogenesis of NOD diabetes is initiated by reactivity to the insulin B chain 9-23 epitope and involves functional epitope spreading. J Autoimmun 39:347-353.
40. Shannon P, Markiel A, Ozier O, Baliga NS, Wang JT, Ramage D, Amin N, Schwikowski B, Ideker T. 2003. Cytoscape: A software environment for integrated models of biomolecular interaction networks. Genome Res 13:2498-2504.
41. Southwood S, Sidney J, Kondo A, del Guercio MF, Appella E, Hoffman S, Kubo RT, Chesnut RW, Grey HM, Sette A. 1998. Several common HLA-DR types share largely overlapping peptide binding repertoires. J Immunol 160:3363-3373.
42. Sprenger J, Lynn Fink J, Karunaratne S, Hanson K, Hamilton NA, Teasdale RD. 2008. LOCATE: A mammalian protein subcellular localization database. Nucleic Acids Res 36:D230-D233.
43. UniProt Consortium. 2012. Reorganizing the protein space at the Universal Protein Resource (UniProt). Nucleic Acids Res 40:D71-D75.
44. Walsh G. 2010. Biopharmaceutical benchmarks 2010. Nat Biotechnol 28:917-924.
45. Wang P, Sidney J, Dow C, Mothe B, Sette A, Peters B. 2008. A systematic assessment of MHC Class II peptide binding predictions and evaluation of a consensus approach. PLoS Comput Biol 4:e1000048.
46. Worobec A, Rosenberg AS. 2004. A risk-based approach to immunogenicity concerns of therapeutic protein products, Part 1: Considering consequences of the immune response to a protein. BioPharm Int 17:22-26.
47. Xu X, Nagarajan H, Lewis NE, Pan S, Cai Z, Liu X, Chen W, Xie M, Wang W, Hammond S, Andersen MR, Neff N, Passarelli B, Koh W, Fan HC, Wang J, Gui Y, Lee KH, Betenbaugh MJ, Quake SR, Famili I, Palsson BO, Wang J. 2011. The genomic sequence of the Chinese hamster ovary (CHO)-K1 cell line. Nat Biotechnol 29:735-741.
48. You S, Chatenoud L. 2006. Proinsulin: A unique autoantigen triggering autoimmune diabetes. J Clin Invest 116:3108-3110.